# US 2021/0341475 A1 · Antibody pairs for use in a rapid influenza a diagnostic test

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341475 A1
- Document ID: US20210341475A1
- Status: Published application
- Kind: A1
- Application number: 16/973,485
- Filed: 2019-06-11
- Published: 2021-11-04
- Earliest claimed: 2018-06-11
- Assignees: GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
- Applicants: GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
- Inventors: Dennis Joseph CHURCH; Anthony NICHOLS
- Web page: https://patentgrep.com/patent/US20210341475A1

## CPC

- G01N 33/54388: {based on lateral flow}
- G01N 33/56983: {Viruses}
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Novel antibody pairs for use in an Influenza A diagnostic test.

## Claims

### Claim 1

A matched antibody pair comprising the detection and capture antibodies in a lateral flow immunoassay to detect Nucleoprotein (NP) antigen of Influenza A present in a sample, wherein the antibodies of said matched antibody pair are independently capable of binding to an NP epitope in the region comprising amino acids 1-60 of Influenza A Nucleoprotein.

### Claim 2 (depends on 1)

A matched antibody pair according to claim 1 wherein the antibodies are capable of binding to an NP epitope independently selected in each case from the group consisting of SQ. ID. Nos. 2 and 3 hereof.

### Claim 3 (depends on 1)

A matched antibody pair according to claim 1 wherein at least one of the antibodies binds to an NP epitope comprising SEQ. ID. NO:2.

### Claim 4 (depends on 1)

A matched antibody pair according to claim 1 wherein the detection and capture antibodies are capable of binding to an NP epitope comprising SEQ. ID. NO: 2.

### Claim 5 (depends on 1)

A matched antibody pair according to claim 1 wherein the detection antibody is Antibodies Online ABIN2489610, clone B248M, and the capture antibody is Meridian CO1731M, clone B1632M.

### Claim 6

A ternary complex comprising:
(a) Influenza A Nucleoprotein (NP);
(b) a detection antibody conjugated with or otherwise associated with a detectible signal; and
(c) a capture antibody, optionally immobilized on a substrate,
wherein (b) and (c) are capable of binding an epitope of (a) independently selected in each case from an NP epitope in the region comprising amino acids 1-60 of Influenza A Nucleoprotein.

### Claim 7 (depends on 6)

A ternary complex according to claim 6 wherein (b) and (c) are capable of binding an epitope of (a) independently selected in each case from the group consisting of SQ. ID. Nos. 2 and 3 hereof.

### Claim 8 (depends on 6)

A ternary complex according to claim 6 wherein at least one of the antibodies is capable of binding to an NP epitope comprising SEQ. ID. NO:2.

### Claim 9 (depends on 6)

A ternary complex according to claim 6 wherein the detection and capture antibodies are capable of binding to an NP epitope comprising SEQ. ID. NO: 2.

### Claim 10 (depends on 6)

A ternary complex according to claim 6 wherein (b) and (c) are, respectively, Antibodies Online ABIN2489610, clone B248M, and Meridian CO1731M, clone B1632M.

### Claim 11 (depends on 6)

A substrate comprising immunochromatographic material having immobilized thereon the ternary complex according to claim 6.

### Claim 12

A lateral flow immunoassay for detecting Influenza A Nucleoprotein (NP) in a sample, comprising:
(a) a mobile phase comprising a detection antibody conjugated or otherwise associated with a detectible signal, said detection antibody being capable of binding NP to form a binary complex; and
(b) a stationary phase comprising a substrate comprising immunochromatographic material having immobilized thereon a capture antibody, said capture antibody being capable of binding said NP of the binary complex to form a ternary complex, whereby a detectible signal generated by said ternary complex is indicative of the presence of NP in the sample,
said capture and detection antibodies being capable of binding an NP epitope in the region comprising amino acids 1-60 of Influenza A Nucleoprotein.

### Claim 13 (depends on 12)

A lateral flow immunoassay according to claim 12 wherein said detection and capture antibodies bind to an NP epitope independently selected in each case from the group consisting of SEQ. ID. NOS: 2 and 3 hereof.

### Claim 14 (depends on 12)

A lateral flow immunoassay according to claim 12 wherein at least one of the antibodies binds to an NP epitope comprising SEQ. ID. NO:2.

### Claim 15 (depends on 12)

A lateral flow immunoassay according to claim 12 wherein the detection and capture antibodies are capable of binding to an NP epitope comprising SEQ. ID. NO: 2.

### Claim 16 (depends on 12)

A lateral flow immunoassay according to claim 12 wherein the detection antibody is Antibodies Online ABIN2489610, clone B248M, and the capture antibody is Meridian CO1731M, clone B1632M.

### Claim 17

A method for detecting Influenza A in a sample using a lateral flow immunoassay comprising a mobile phase and a stationary phase, said method comprising
(a) introducing said sample to the mobile phase of said assay,
(b) contacting Influenza A Nucleoprotein (NP) in said sample with at a detection antibody that is conjugated or otherwise associated with a detectible signal to form a binary complex comprising said detection antibody and NP in said mobile phase, and
(c) contacting said mobile phase with a stationary substrate comprising immunochromatographic material having immobilized thereon a capture antibody, said capture antibody being capable of binding said NP of the binary complex to form a ternary complex, whereby a detectible signal generated by said ternary complex is indicative of the presence of NP in the sample,
wherein said capture antibody and said detection antibody are capable of binding an NP epitope in the region comprising amino acids 1-60 of Influenza A Nucleoprotein.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 12)

A method for diagnosing a patient afflicted with Influenza A comprising testing a biological sample from the patient in a lateral flow immunoassay according to claim 12, and determining the presence of Influenza A Nucleoprotein, wherein the presence of a detectible signal is indicative of Influenza A infection in said patient.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 12)

A method for monitoring the efficacy of therapeutic treatment of Influenza A in a patient by testing a biological sample from the patient in a lateral flow immunoassay according to claim 12, and determining the presence or absence of Influenza A Nucleoprotein, prior to and following administration of a pharmaceutical active agent for treating Influenza A.

### Claim 26 (depends on 12)

A medical device comprising the lateral flow immunoassay according to claim 12.

### Claim 27 (depends on 12)

A kit comprising the lateral flow immunoassay according to claim 12 in a housing, and optionally, a reader device and/or instructions for use of the kit.
